Change of Guard at the Helm - Report on Juniper Pharmaceuticals, Inc.

Aug 04, 2015, 09:10 ET from

NEW YORK, August 4, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Juniper Pharmaceuticals, Inc. (NASDAQ: JNP). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL:  

Highlights from our JNP Report include:

  • Appointment of New Chairman - On July 16, 2015, Juniper Pharmaceuticals, Inc. (Juniper) announced several changes to its Board of Directors. The specialty pharmaceutical company focused on developing women-related therapeutics informed that James A. Geraghty has been appointed as new Chairman of the Board, coinciding with the retirement of current Chairman Steven Kasnet.
  • Credentials of the New Head - Having 30 years of strategic and leadership experience, Mr. Geraghty is presently an Entrepreneur in Residence at Third Rock Ventures and also Chairman of the Board of Idera Pharmaceuticals. He worked for 20 years for Genzyme in various roles, including Senior Vice President International Development, President of Genzyme Europe, and General Manager of Genzyme's cardiovascular business. Upon acquisition of Genzyme by Sanofi, Mr. Geraghty worked as Senior Vice President, North America Strategy and Business Development at Sanofi. In terms of educational qualifications, Mr. Geraghty holds a graduate degree from the Yale Law School and a Bachelor of Arts degree from Georgetown University. He also has pursued Master of Science from the University of Pennsylvania.
  • Appointment to the Board - Juniper also announced the appointment of Ann Merrifield as the Board's director. Ms. Merrifield worked as President and Chief Executive Officer of PathoGenetix, prior to joining this organization. Before joining PathoGenetix, she spent 18 years at the Genzyme Corporation where, among other roles, she served as Senior Vice President, Business Excellence; President of Genzyme Biosurgery and President of Genzyme Genetics. Moreover, she was previously a partner at a global management consulting firm Bain and Company and an investment officer at Aetna Life & Casualty. While describing her professional qualifications, the Company stated that Ms. Merrifield pursued Bachelor of Arts in Zoology and Master of Education from the University of Maine. She also has earned a degree of Master of Business Administration from the Amos Tuck School of Business at Dartmouth College.
  • Other Board Changes - The Company further informed that Valerie Andrews, Director, and Donald Hunter, Chair of the Audit Committee, resigned from the Board, as previously announced by the Company in an 8-K filing following its Annual Meeting of Shareholders, held earlier in July 2015. While Ms. Andrews' resignation took immediate effect, Mr. Hunter's resignation was accepted by Juniper's Board, effective immediately upon the appointment of his successor.

To find out how this influences our rating on Juniper Pharmaceuticals, Inc., read the full report in its entirety here:

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.


ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at)

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.